FDA Approves New Nasal Spray <br />to Treat Depression Spravato nasal spray, also known as esketamine, can now be used for treatment-resistant depression. Esketamine is related to ketamine, <br />known as 'Special K,' a drug that <br />became a controlled substance <br />in 1999. Dr. Tiffany Farchione, FDA, via news release Patients who have tried at least two antidepressants are considered to have treatment-resistant depression. About one-third of U.S. adults with a major depressive disorder have treatment-resistant depression, according to Janssen Pharmaceutical Companies. Spravato should be used in conjunction with an <br />oral antidepressant, according to the FDA. The spray cannot be taken home and can only be administered in a certified doctor's office. Dr. Mathai Mammen Janssen, via statement
